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Abstract
Background: Xylitol is a naturally occurring sugar substitute that has been shown to reduce the
level of mutans streptococci in plaque and saliva and to reduce tooth decay. It has been suggested
that the degree of reduction is dependent on both the amount and the frequency of xylitol
consumption. For xylitol to be successfully and cost-effectively used in public health prevention
strategies dosing and frequency guidelines should be established. This study determined the
reduction in mutans streptococci levels in plaque and unstimulated saliva to increasing frequency
of xylitol gum use at a fixed total daily dose of 10.32 g over five weeks.
Methods: Participants (n = 132) were randomized to either active groups (10.32 g xylitol/day) or
a placebo control (9.828 g sorbitol and 0.7 g maltitol/day). All groups chewed 12 pieces of gum per
day. The control group chewed 4 times/day and active groups chewed xylitol gum at a frequency
of 2 times/day, 3 times/day, or 4 times/day. The 12 gum pieces were evenly divided into the
frequency assigned to each group. Plaque and unstimulated saliva samples were taken at baseline
and five-weeks and were cultured on modified Mitis Salivarius agar for mutans streptococci
enumeration.
Results: There were no significant differences in mutans streptococci level among the groups at
baseline. At five-weeks, mutans streptococci levels in plaque and unstimulated saliva showed a
linear reduction with increasing frequency of xylitol chewing gum use at the constant daily dose.
Although the difference observed for the group that chewed xylitol 2 times/day was consistent with
the linear model, the difference was not significant.
Conclusion: There was a linear reduction in mutans streptococci levels in plaque and saliva with
increasing frequency of xylitol gum use at a constant daily dose. Reduction at a consumption
frequency of 2 times per day was small and consistent with the linear-response line but was not
statistically significant.
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Background
Xylitol is a naturally occurring sugar alcohol that has been
shown to markedly reduce tooth decay. The substitution
of xylitol for sucrose in confections and foods may signif-
icantly decrease dental caries (for reviews see [1-3]). Pub-
lished studies and prevention programs using xylitol have
followed the dose and frequency of earlier studies which
showed reductions in caries and where the daily xylitol
dose varied from 4 to 11 g divided into three to five doses
and delivered primarily via chewing gum. Studies using
dose of 4 to 5 g or less of xylitol per day have reported con-
flicting results [4,5]. Table 1 summarizes selected pub-
lished clinical trials where different formulations of
xylitol chewing gum were used to evaluate their effective-
ness in reducing mutans streptococci and dental caries
[see Additional file 1]. These prospective trials were
designed to assess the reduction in caries or mutans strep-
tococci levels and not designed to assess the dose or fre-
quency of xylitol use relationship to the reductions.
Isokangas [6] retrospectively divided the subjects of a
study into three subgroups by the daily average frequency
of self-reported xylitol gum chewing and concluded that
caries reduction was observed at consumption frequency
of three times per day, but not at 2.5 times or less doses
per day. The latter groups did not differ from the
untreated controls. Subsequently, Rekola [7] used data
from another study to retrospectively assess the frequency-
response relationship of xylitol chewing gum and caries.
The study concluded that there was a frequency-response
relationship where xylitol chewing gum reduces the caries
increment (∆DMFS) with increased frequency of con-
sumption.
This study is the second in a series of prospective studies
designed to enhance the science base for the use of xylitol
in population-based prevention programs. The initial
study showed a linear reduction of mutans streptococci
(defined to include both S. mutans and S. sobrinus species)
in plaque and unstimulated saliva to increasing xylitol
dose up to 6.88 g/day. The reduction leveled-off between
6.88 g/day and 10.32 g/day. For the smallest dose of 3.44
g/day, a reduction was observed but did not reach statisti-
cal significance. These results were consistent at five-weeks
and at 6-months. All subjects in the study chewed 3 pieces
of xylitol and/or sorbitol gum 4 times per day [8]. This
dose-response relationship is in agreement with a recent
study conducted in Thailand where a difference between
xylitol dose of 5.8 g/day and 11.9 g/day was not observed
[9].
The aim of this second study was to prospectively deter-
mine the relationship between the frequency of xylitol
gum use and mutans streptococci level. This paper inves-
tigates the hypothesis that there is a linear reduction in
mutans streptococci level in plaque and unstimulated
saliva over five-weeks in response to increasing frequency




Potential subjects from the Seattle, WA area (n = 352)
were interviewed for medical conditions and antibiotic
use that would preclude participation. Individuals were
excluded if they had taken antibiotics during the last four
weeks or anticipated doing so during the study. Subjects
with a history of gastrointestinal problems were excluded,
as were subjects intolerant to phenylalanine. Screening
plaque samples were taken and processed for mutans
streptococci enumeration from potential subjects who
met the inclusion criteria (n = 337). Of these, 177 subjects
with ≥ 104 CFU mutans streptococci/ml in their sample
were invited to participate. An additional six who were
screened and met the criteria but were not invited to par-
ticipate because enrollment had closed by the time their
results were available. Among those invited to participate,
75% (132/177) of subjects completed all baseline proce-
dures and were enrolled. The Institutional Review Board
of the University of Washington approved this study and
the informed consent of the participants was obtained.
Study design
This prospective randomized, controlled, clinical trial
employed a four-group design in which each active group
consumed 10.32 g/day of xylitol delivered in chewing
gum. The daily 12 xylitol gum pellets were evenly divided
into chewing frequency groups of 2, 3, or 4 times/day,
denoted as group F2, F3, or F4, respectively. The control
group (F0) consumed 12 sorbitol chewing gum pellets
evenly divided into 4 times/day. For subjects in the gum
use frequency of 4 times/day, study staff and subjects were
blinded to their group assignment. Subjects were ran-
domly assigned to groups using a computer generated
block randomization procedure. Block randomization
was selected to ensure similar proportion of participants
in each group. The codes for assignment were kept by the
biostatistician and were decoded at the end of the study.
Plaque and unstimulated saliva samples were taken at
baseline and five-weeks of exposure. Five-weeks was
selected because in the first study in this series, mutans
streptococci levels were consistent between five-weeks
and six months of exposure and because a shorter study
period aided recruitment and reduced subject burdens.
The study was carried out at the University of Washington
Regional Clinical Dental Research Center.
Gum
Both xylitol and control (sorbitol) gums used in this study
were the same as those in the first study in the series [8].BMC Oral Health 2006, 6:6 http://www.biomedcentral.com/1472-6831/6/6
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Each xylitol pellet contained 0.858 g xylitol plus gum
base, peppermint, menthol, gum Arabic, glycerol, soy lec-
ithin, and glazing agents. Each pellet of the control gum
contained the same non-active ingredients plus 0.819 g
sorbitol, 0.059 g maltitol, and 0.0015 g Acesulfame K. All
gum pellets were formulated by Fennobon Oy (Karkkila,
Finland) to be similar in size, consistency, color and
sweetness.
Sample size
The sample size was determined based on intent-to-treat
and to provide sufficient power to test the hypothesis that
mutans streptococci in plaque and saliva will decrease in
response to increasing frequency of xylitol. For the fre-
quency effect analysis, mutans streptococci counts were
transformed to log10 scale and linear regression was used.
A planned sample size of n = 26 subjects per group pro-
vided 81% power (2-sided, α = 0.05), where a difference
in total mutans streptococci count between the lowest and
highest groups was assumed to be log0.75  = 5.6-fold.
Assuming a loss to follow-up of 10% to 20%, a total
recruitment of 33 subjects per group was necessary to
ensure an adequate minimum sample size.
Adherence
Participants were intensively coached on development of
a daily routine for gum chewing and asked to chew the
gum for at least five minutes. Pre-packed daily gum pack-
ets were distributed at baseline, and after the first and
third week of exposure. At each visit, the participant's
chewing log was reviewed to monitor compliance and if
necessary, an individualized daily gum use schedule was
developed and coached based on examination of the par-
ticipant's daily habits.
Each group chewed 12 pieces of gum per day. To enhance
compliance, participants in group F2 (6 pellets each dose,
2 times/day) and group F3 (4 pellets each dose, 3 times/
day) were instructed that they could break a dose up into
sets of 2 or 3 pellets and chew each set for at least five min-
utes, one set immediately after the other, and to complete
chewing all the gums for each dose within 15 to 20 min-
utes.
Plaque and unstimulated saliva sampling
Plaque and unstimulated saliva sampling and laboratory
methods were the same as in the first study of the series.
First, plaque samples were collected from the cervical
third of the buccal surfaces of all teeth using one sterile
Kerr applicator per arch and placed in a 5 ml tube contain-
ing glass beads and 1 ml of pre-reduced saline. Then, sub-
jects were instructed to let saliva collect without
swallowing for at least one minute and then expectorate
into the collection tube. This process was repeated as nec-
essary until the minimum 1 ml of saliva was collected. The
tubes were immediately carried to the laboratory where
they were stored at room temperature until processed gen-
erally within three hours. However, samples delivered
after 3:30 p.m. were not processed until the following
morning (15–17 hours) after delivery. No differences in
total counts were observed between samples processed
the same day or the following morning. Study staff was
trained to conduct plaque and saliva samplings.
Culture of mutans streptococci
Samples were taken from study participants at baseline
and five-weeks after enrollment. Plaque was prepared in
pre-reduced saline and 10-fold dilutions of plaque and
saliva were prepared separately. For each sample, a modi-
fied Mitis-Salivarius agar (Difco Laboratories) supple-
mented with 500 µg/ml kanamycin, 1% potassium
tellurite solution, and 50 U/ml bacitracin (MSKB) was
used to enumerate mutans streptococci. The MSKB
medium is more specific than MSB for mutans strepto-
cocci isolation [10,11] but does not distinguish between
S. mutans and  S. sobrinus. Thus, mutans streptococci
counts from MSKB plates in this report included both of
these species. Only freshly prepared plates were used.
The plaque samples were vortexed to break up the plaque.
Then, plaque and saliva samples were diluted. The 10-0 to
10-3 dilutions were plated on MSKB media and incubated
in 5% CO2 at 36.5°C for seven days prior to enumeration.
In the first study of this series, DNA probes (SSP001 and
SM002/SM010) specific for the rRNA variable region of S.
mutans and S. sobrinus [10] were used to verify that only
mutans streptococci colonies were counted. Greater than
90% of the randomly selected 1,400 colonies from the
MSKB media hybridized indicating that the counted colo-
nies were either S. mutans or S. sobrinus. This verification
process was not repeated in this study.
Statistical procedures
Linear regression was used to assess the hypothesis of lin-
ear frequency-response of mutans streptococci levels after
five-weeks of xylitol chewing gum exposure. The linear-
response model was based on the formula: Y = ax1 + bx2 +
e, where y = log10 saliva or plaque at five-weeks, x1 = log10
saliva or plaque at baseline, x2 = frequency (2, 3, or 4
times/day), and e = error. Potential additional terms used
in the analyses process includes: x3 = dose*dose, to check
for nonlinear response, and x3 = gender dummy variable
or x3 = antibiotic dummy variable to determine signifi-
cance of gender or antibiotics use during the follow-up
period. The α-value was set at α < 0.10 as an entry crite-
rion. Where appropriate, descriptive statistics, t-test, anal-
ysis of the variance (ANOVA), and least-significant-
difference multiple-comparisons test were used to deter-
mine differences between the groups at baseline, at five-BMC Oral Health 2006, 6:6 http://www.biomedcentral.com/1472-6831/6/6
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weeks, and among baseline and five-weeks. The SPSS
(v.11.5) and SAS (v.8e) statistical software were used.
Results
Baseline
The 132 participants had a mean age of 34 years (range,
18–73), and 57% were women. Participants were 78%,
9%, and 5% Caucasian, Asian, and African American,
respectively. Nearly 8% of participants were either His-
panic, Native American or self-identified as mixed race or
ethnicity.
The four groups each included 33 participants (n = 132),
with females ranging from 42% to 67% in the different
groups. Racial distribution among the groups was similar
with a predominance of Caucasian (76% to 85%). The
mean (range) age of the groups was also similar, 34.5 (19,
70), 34.1 (19, 64), 37.2 (19, 73), 34.1 (18, 60) years for
groups F0, F2, F3, and F4, respectively.
There were no statistical differences in mean log10 mutans
streptococci levels for plaque (F = 0.41, p = 0.75) and
unstimulated saliva (F = 0.90, p = 0.45) among the groups
at baseline. At the five-week follow-up, 95% (n = 126) of
the participants returned for plaque and unstimulated
saliva samples collection (F0 = 32, F2 = 31, F3 = 31, F4 =
32). Excluding the dropouts from the analysis did not pro-
duce a significant change in the mean log10 mutans strep-
tococci counts for each group at baseline.
Hypothesis testing
The five-week plaque and saliva samples showed a linear-
frequency response where decreases in mutans strepto-
cocci levels were associated with higher frequency of xyli-
tol gum chewing at a total daily dose of 10.32 g. The slope
of the linear-frequency response was slightly greater for
plaque (-0.21) than for unstimulated saliva (-0.19) (Fig-
ure 1).
In a sub-analysis, levels of mutans streptococci were sig-
nificantly different for groups F3 and F4 (p < 0.10) relative
to the control group at five-weeks. There was a difference
in mutans streptococci levels between group F2 and the
control but the difference did not reach statistical signifi-
cance. Nevertheless, this difference for group F2 was con-
sistent with the hypothesized linear-frequency response
model (Figure 1).
Discussion
This study is part of a series to determine the minimum
dose (g/day) and frequency (number of administrations/
day) required for xylitol chewing gum to be effective in
reducing mutans streptococci levels in plaque and saliva.
These studies are important to establish the minimum
effective dose and frequency for the use of xylitol in public
health programs. Adoption of xylitol use in the United
States has been hindered by the absence of such data.
The study design controls for total daily xylitol dose and
number of gum pellets chewed. Frequency of xylitol con-
sumption was varied by dividing the total daily numbers
of pellets into two, three, or four consumption periods.
The results demonstrated a linear-response relationship
between the increasing frequency of xylitol gum use and
the reduction in the level of mutans streptococci in plaque
and unstimulated saliva after five-weeks of exposure. This
is consistent with the retrospective studies by Isokangas
[6] and Rekola [7] as well as with several other studies
where this trend was observed. However, none of these
studies was designed to determine the dose- or frequency-
response relationships; but rather, they were designed as
intervention trials to determine the effect on reduction of
caries and/or mutans streptococci levels.
The sub-analysis assessed the differences between test and
control groups at each frequency of xylitol gum use. The
smaller reduction observed for the group F2 with a fre-
quency of twice per day did not reach significance. How-
ever, the observed reduction falls within the range of the
hypothesized linear-response slope. Thus, although
small, the observed reduction is likely to be real and not
by chance. This is also consistent with the retrospective
study by Isokangas [6] in which the author concluded that
consumption at 2.5 times per day or less produced no sig-
nificant reduction in caries.
Mutans streptococci counts in plaque and unstimulated Saliva  at five weeks and best fit linear line Figure 1
Mutans streptococci counts in plaque and unstimu-
lated Saliva at five weeks and best fit linear line. Linear 
reduction of mutans streptococci levels in plaque and unstim-
ulated saliva to increasing frequency of xylitol chewing gum 
use at a constant daily dose (10.32 g/day). Linear line equa-
tions: plaque – *log mutans streptococci = -.21(Frequency) + 
5.21; unstimulated saliva – **log mutans streptococci = -
.19(Frequency) + 5.07. Group F0 = Sorbitol Control; F2 = 
xylitol 2x/d; F3 = xylitol 3x/d; F4 = xylitol 4x/d.BMC Oral Health 2006, 6:6 http://www.biomedcentral.com/1472-6831/6/6
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A plateau effect which was observed for xylitol dose
reported in the first study of the series was not present in
this study. This suggests that although higher frequency
maybe more effective in reducing mutans streptococci lev-
els in plaque and saliva, the overall reduction may be lim-
ited by the dose plateau. In the Belize intensive
intervention trial, the group from the original cohort who
had used sucrose gum was selected and given xylitol gum
7 times/day (unsupervised chewing), giving an average
daily dose of 14 g. Substantial reductions in both mean
DMFS scores and caries rate were observed. However, the
author was not able to conclude that the intensive inter-
vention produced better results than those reported in the
original study where both dose and frequency of xylitol
use were less [12].
This study had several limitations. Plaque collection was
not standardized by plaque weight but rather by sampling
the arches of teeth. This may be viewed as qualitative and
may affect the quantitative analysis. However, the effect is
minimized by standardization of sampling and by train-
ing of staff. Furthermore, plaque samples at screening
compared to baseline and among controls throughout the
study did not yield differences in mutans streptococci
level. The study used unstimulated saliva to control for
mechanical dislodging of mutans streptococci from
plaque and falsely or inconsistently increasing mutans
streptococci levels.
The two studies in this series thus far confirm what xylitol
researchers have speculated for sometime. Studies have
shown that xylitol is effective in reducing mutans strepto-
cocci in plaque as well as unstimulated saliva (Table 1 [see
Additional file 1]). This series of studies as well as other
retrospective studies and prospective intervention trials
(Table 1) have established that xylitol in the amount of
3.4 g/day or less is unlikely to be effective; amounts
greater than 10 g/day are unlikely to yield further reduc-
tions; and frequency of exposure of 3 times/day or more
is necessary for effectiveness. This knowledge is highly sig-
nificant in considering the feasibility of public health pre-
vention programs using xylitol.
Xylitol-based caries preventive programs may be more
effective in structured daycare centers, Head Start, or at
school where the environment offers the best opportunity
to achieve compliance. It would be a great challenge to
develop home-based prevention programs where a task,
any task, consistently requires attention 3 times/day. This
is particularly true among the poor and disadvantaged
where the stress of day-to-day living already consumes the
bulk of their attention. These results also suggest that basic
science studies are needed that would help better deline-
ate the mechanisms of action of xylitol so that food prod-
ucts can be engineered to reduce the required frequency
and dose of use.
Finally, while xylitol chewing gum at the proper amount
and frequency will reduce tooth decay, chewing gum is
only a good xylitol vehicle for some populations or age
groups. Most school systems in the United States do not
advocate for the regular use of chewing gum in the class-
room. In many schools, chewing gum is simply prohib-
ited. Autio and Courts [13] found that acceptance of
chewing gum in the classroom by teacher was low. In
other instances, the children may be too young to safely
chew gum. The American Academy of Pediatrics' guide-
lines for choking prevention listed chewing gum among
the foods not to give to children under four years of age.
With this in mind, the last two studies in this series will
compare the effectiveness of xylitol delivered via different
snack foods.
Conclusion
This study found a linear response relationship between
the reduction of mutans streptococci levels in plaque and
unstimulated saliva and the increase in frequency of xyli-
tol chewing gum use. The reduction observed for xylitol
chewing gum use of 2 times/day was small but consistent
with the linear response line. However, this reduction was
not statistically different from the sorbitol control.
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